Electra Therapeutics
A clinical stage biotech developing antibody therapies against novel targets for immunological diseases and cancer.
As of Q1 2024, Electra has one program in clinical development and additional preclinical programs.
The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and precisely depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition for which there is no approved treatment.
Latest Electra Therapeutics News & Features
13 December 2023
17 February 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze